Home/Pipeline/NFL-102

NFL-102

Smoking Cessation

Phase 2Active

Key Facts

Indication

Smoking Cessation

Phase

Phase 2

Status

Active

Company

NFL Biosciences

About NFL Biosciences

NFL Biosciences is a clinical-stage biotech focused on botanical drug candidates for substance addictions, including tobacco, alcohol, and cannabis. Its most advanced program, NFL-101 for smoking cessation, has completed three clinical studies, with a related candidate, NFL-102, also in clinical progress. The company went public in 2021, raising €14 million, and leverages a capital-efficient, outsourced research model while holding five patent families to protect its innovative approach.

View full company profile

Therapeutic Areas

Addiction Smoking Cessation Alcohol Use Disorder

Other Smoking Cessation Drugs

Drug	Company	Phase	Status
Nicotine Nasal Spray	Biodeal Pharmaceuticals	Commercial	Active
NIH Grant Program (with Johns Hopkins)	CTT Pharma	Grant Pending	Pending Decision
Smoking Cessation Program	Qnovia	Pre-clinical	Active
Platform Expansion	Amygdala Neurosciences	Research	Active
NFL-101	NFL Biosciences	Phase 2	Active
Varenicline Tablets	Indoco Remedies	Approved	Commercial Launch Pending
DehydraTECH-Nicotine	Lexaria Bioscience	Human Clinical	Active